Authorization

CES 2021 MedFluid Develops First-In-Class Microfluidic Platform for Rapid Detection and Screening of Disease Diagnosis

TAIPEI, Taiwan, Jan. 17, 2021 /PRNewswire/ -- Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients.
CES 2021 MedFluid Develops First-In-Class Microfluidic Platform for Rapid Detection and Screening of Disease Diagnosis
MedFluid Founder and Head of Microfluidics R&D Bon Lee noted that, according to the World Health Organization (WHO), antimicrobial resistance was one of the ten threats to global health in 2019. "It is happening around the world, and North America alone has more than 2 million cases and 23 thousand deaths.""Global research shows that 50% usage of antibiotics is inappropriate, and empirical treatment is one of the main causes. Empirical treatment usually gives 2~3 antibiotics at the same time to suppress unknown bacteria.However, no medical device currently in the market is able to conduct an antibiotics combination test to either confirm or predict if a combination is effective. Moreover, the current, time-consuming procedure for antimicrobial susceptibility test (AST) needs to be addressed urgently."
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2021    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
293031